Orgenesis (ORGS) Competitors $1.33 -0.20 (-13.07%) As of 07/3/2025 12:46 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ORGS vs. INKT, COEP, SXTC, SCYX, NRSN, TPST, CARA, TENX, LSTA, and CYTHShould you be buying Orgenesis stock or one of its competitors? The main competitors of Orgenesis include MiNK Therapeutics (INKT), Coeptis Therapeutics (COEP), China SXT Pharmaceuticals (SXTC), SCYNEXIS (SCYX), NeuroSense Therapeutics (NRSN), Tempest Therapeutics (TPST), Cara Therapeutics (CARA), Tenax Therapeutics (TENX), Lisata Therapeutics (LSTA), and Cyclo Therapeutics (CYTH). These companies are all part of the "pharmaceutical products" industry. Orgenesis vs. Its Competitors MiNK Therapeutics Coeptis Therapeutics China SXT Pharmaceuticals SCYNEXIS NeuroSense Therapeutics Tempest Therapeutics Cara Therapeutics Tenax Therapeutics Lisata Therapeutics Cyclo Therapeutics MiNK Therapeutics (NASDAQ:INKT) and Orgenesis (NASDAQ:ORGS) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, dividends, media sentiment, risk and earnings. Which has more risk and volatility, INKT or ORGS? MiNK Therapeutics has a beta of 0.19, meaning that its stock price is 81% less volatile than the S&P 500. Comparatively, Orgenesis has a beta of 0.47, meaning that its stock price is 53% less volatile than the S&P 500. Do analysts prefer INKT or ORGS? MiNK Therapeutics currently has a consensus target price of $37.50, suggesting a potential upside of 445.77%. Given MiNK Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe MiNK Therapeutics is more favorable than Orgenesis.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MiNK Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Orgenesis 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media refer more to INKT or ORGS? In the previous week, MiNK Therapeutics' average media sentiment score of 0.00 equaled Orgenesis'average media sentiment score. Company Overall Sentiment MiNK Therapeutics Neutral Orgenesis Neutral Which has preferable earnings & valuation, INKT or ORGS? MiNK Therapeutics has higher earnings, but lower revenue than Orgenesis. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMiNK TherapeuticsN/AN/A-$9.51M-$2.52-2.73Orgenesis$662K9.64-$55.36MN/AN/A Do insiders & institutionals have more ownership in INKT or ORGS? 2.9% of MiNK Therapeutics shares are held by institutional investors. Comparatively, 22.6% of Orgenesis shares are held by institutional investors. 22.5% of MiNK Therapeutics shares are held by insiders. Comparatively, 5.7% of Orgenesis shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Is INKT or ORGS more profitable? MiNK Therapeutics has a net margin of 0.00% compared to Orgenesis' net margin of -3,827.81%. Company Net Margins Return on Equity Return on Assets MiNK TherapeuticsN/A N/A -140.72% Orgenesis -3,827.81%N/A -130.18% SummaryMiNK Therapeutics beats Orgenesis on 6 of the 10 factors compared between the two stocks. Get Orgenesis News Delivered to You Automatically Sign up to receive the latest news and ratings for ORGS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ORGS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ORGS vs. The Competition Export to ExcelMetricOrgenesisPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.38M$790.73M$5.53B$9.05BDividend YieldN/A4.84%5.24%4.02%P/E RatioN/A1.3527.5120.24Price / Sales9.64226.97416.89118.64Price / CashN/A23.4436.8958.07Price / Book-0.206.298.035.67Net Income-$55.36M-$27.73M$3.18B$249.13M7 Day Performance-11.33%1.82%2.90%3.28%1 Month Performance-24.00%9.90%3.71%5.56%1 Year PerformanceN/A10.79%36.03%21.13% Orgenesis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ORGSOrgenesisN/A$1.33-13.1%N/AN/A$6.38M$662K0.00150Gap UpINKTMiNK Therapeutics3.2844 of 5 stars$7.34+5.2%$37.50+410.9%-23.8%$27.82MN/A-2.9130COEPCoeptis Therapeutics0.1962 of 5 stars$7.80+0.3%N/A+37.9%$27.34MN/A-1.342Gap UpSXTCChina SXT Pharmaceuticals0.1422 of 5 stars$1.73+0.6%N/A-78.3%$27.22M$1.82M0.0090News CoverageSCYXSCYNEXIS0.2706 of 5 stars$0.67-2.4%N/A-62.3%$26.98M$3.75M-1.2060NRSNNeuroSense Therapeutics1.7252 of 5 stars$1.89-0.5%$14.00+640.7%+44.7%$25.97MN/A-3.5010TPSTTempest Therapeutics1.796 of 5 stars$6.80-1.4%$30.00+341.2%-74.0%$25.41MN/A-0.3820News CoverageCARACara Therapeutics0.3513 of 5 starsN/AN/AN/A$24.33M$7.14M-0.2580News CoverageGap DownHigh Trading VolumeTENXTenax Therapeutics1.2977 of 5 stars$5.76-1.5%$17.50+203.8%+87.4%$24.27MN/A-2.329LSTALisata Therapeutics2.519 of 5 stars$2.90+3.6%$15.00+417.2%-23.0%$24.12M$1M-1.2630Gap DownCYTHCyclo TherapeuticsN/A$0.72flat$0.95+31.8%N/A$23.72M$870.73K-0.809 Related Companies and Tools Related Companies MiNK Therapeutics Alternatives Coeptis Therapeutics Alternatives China SXT Pharmaceuticals Alternatives SCYNEXIS Alternatives NeuroSense Therapeutics Alternatives Tempest Therapeutics Alternatives Cara Therapeutics Alternatives Tenax Therapeutics Alternatives Lisata Therapeutics Alternatives Cyclo Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ORGS) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Orgenesis Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Orgenesis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ORGS Stock Alerts